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Background: There have been limited evidences regarding optimal treatment options
for in-stent restenosis (ISR). We performed a Bayesian network meta-analysis
comparing the efﬁcacy and safety of drug-eluting balloon (DEB), drug-eluting stent
(DES), or plain old balloon angioplasty (POBA) for treatment of ISR.
Methods: Randomized controlled trials (RCTs) comparing DEB, DES, or POBA for
treatment of ISR developed after PCI with bare-metal stent (BMS) or drug-eluting
stent (DES) were included to this network meta-analysis. The primary outcome was
target lesion revascularization (TLR) after treatment of ISR. The secondary outcomes
were myocardial infarction (MI), all-cause mortality, MACE, or binary restenosis at
follow-up angiography. The pairwise posterior median OR with 95% CrI in Bayesian
meta-analysis was the effect measure.
Results: This analysis included 2,059 patients from 11 RCTs. The risk of TLR
was markedly lower in patients treated with DEB (OR 0.22, 95% CrI 0.10-0.42) or
DES (OR 0.24, 95% CrI 0.11-0.47), compared with POBA in random-effects
model. The binary restenosis was also signiﬁcantly lower in DEB (0.13, 95% CrI
0.06-0.25) or DES (OR 0.20, 95% CrI 0.09-0.40), compared with POBA. In
comparison between DEB and DES, the risk of TLR (OR 0.92, 95% CrI 0.43-
1.90) or binary restenosis (OR 0.66, 95% CrI 0.31-1.30) was similar. The risk of
MI or all-cause mortality were lowest in DEB group compared with DES or
POBA, however, statistical signiﬁcance were not reached. The rate of MACE was
also signiﬁcantly lower in DEB (OR 0.24, 95% CrI 0.12-0.39) or DES (OR 0.28,
95% CrI 0.14-0.53) group, compared with POBA, but it was similar between DEB
and DES group (OR 0.84, 95% CrI 0.45-1.50). No signiﬁcant inconsistency or
heterogeneity was found across trials. The ranking probabilities for the best
treatment were 59.9% (DEB), 40.1% (DES), and 0.1% (POBA) for the risk of
TLR, whereas, 63.0% (DEB), 1.7% (DES), 35.3% (POBA) for the risk of MI,
respectively.
Conclusions: DEB or DES showed markedly superior efﬁcacy compared with POBA.
Although DEB and DES showed similar efﬁcacy for preventing repeat revasculari-
zation, DEB showed trend for less development of MI, compared with DES in this
network meta-analysis.
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Background: Drug-releasing balloons have shown promising results in femo-
ropopliteal disease; however, adequate evidence demonstrating improved outcomes in
infrapopliteal arteries is currently lacking. BIOLUX P-II assesses the safety and
performance of the novel BIOTRONIK Passeo-18 Lux Paclitaxel-releasing balloon
compared to the uncoated BIOTRONIK Passeo-18 balloon (POBA) in the treatment
of infrapopliteal lesions.
Methods: BIOLUX P-II is a prospective, international, multicenter, ﬁrst-in-human,
randomized, controlled trial with follow-ups at 30 days, 6 and 12 months. Sub-
jects with single or sequential, de novo or restenotic lesions in the infrapopliteal
arteries (30 mm) were included in the study. A maximum of two different
vessels could be treated. The safety primary endpoint was Major Adverse Events
(MAE) at 30 days (adjudicated by an independent Clinical Events Committee).
The performance primary endpoint was Target Lesion Primary Patency at 6
months by Quantitative Vascular Angiography (assessed by an independent core
laboratory, coreLab Bad Krozingen, Germany). Secondary endpoints included
freedom from TLR and change in ABI and Rutherford Class. Clinicaltrials.gov:
NCT01867736.
Results: Seventy-two subjects, 79.2% men, mean age 71.39.7 years, were ran-
domized 1:1 at six European sites. At baseline, subjects presented with hypertension
(86.1%), hyperlipidemia (68.1%), diabetes (66.7%) and critical limb ischemia
(77.8%). At 30 days, MAE was 0.0% for the DRB vs. 8.3% for POBA, p¼0.239. At
6 months, target lesion primary patency showed a trend in favor of the DRB ofJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Dr84.3% vs. 75.9% for POBA, p¼0.330 and major amputations were 3.3% for DRB
vs. 5.7% for POBA, p¼0.655. Clinical improvement at 6 months, reﬂected by
improvement in Rutherford class was 59% in favor of DRB vs. 47% for POBA, with
0% of DRB subjects worsening vs. 6% POBA, p¼0.326. Clinical improvement of
Rutherford 5 subjects was signiﬁcant for the DRB group (p¼0.002) compared to
POBA (p¼0.058).
Conclusions: The Passeo-18 Lux DRB, as compared to POBA, is associated with
favourable functional and clinical outcomes and results in signiﬁcant clinical
improvement of Rutherford 5 subjects in the treatment of infrapopliteal lesions.
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Background: Drug-eluting stents (DES) signiﬁcantly reduce the occurrence of
restenosis and the subsequent need for repeat revascularization. Nevertheless, the
incidence of DES restenosis remains high due to the continuous increase in DES
implantation. Paclitaxel-coated balloon (PCB) angioplasty is superior to plain old
balloon angioplasty (POBA) and noninferior to paclitaxel-eluting stent (PES) im-
plantation for bare-metal stent restenosis. Whether the use of PCB angioplasty is
also effective in DES restenosis remained contraversial. Thus, We performed a
meta-analysis to assess the safety and efﬁcacy of PCB for the treatment of DES
restenosis.
Methods: Trials were identiﬁed through a literature search from January 2005 through
April 2014. All randomized controlled trials were eligible for inclusion if they
compared PCB with a control treatment (POBA or DES) in patients with DES
restenosis. Main endpoints of interest were major adverse cardiac events (MACE),
target lesion revascularisation (TLR), binary in-segment restenosis, myocardial
infarction (MI) and mortality. A random-effects model was used to calculate the
pooled relative risks (RR) with 95% CIs.
Results: Five studies and a total of 864 patients were included in this analysis.
Follow-up duration ranged from 6 to 12 months. Most endpoints were signiﬁcantly
reduced for PCB compared with the control groups. For MACE, the relative risk RR
was 0.49 (0.28 to 0.85), p ¼ 0.012; for TLR, it was 0.50 (0.25 to 0.98), p ¼ 0.044; for
angiographic in-segment restenosis, it was 0.41 (0.23 to 0.72), p ¼ 0.002. There was a
lower mortality for DEB (RR 0.29 [0.11 to 0.80]; p ¼ 0.017). The incidence of MI
was numerically lower, but the differences were not statistically signiﬁcant (RR 0.76
[0.30 to 1.89]; p ¼ 0.549).
Conclusions: In-stent restenosis remains an important issue even in the DES era, and
PCB angioplasty is a promising option for the treatment of DES restenosis. It reduces
the risk for MACE compared with POBA or implantation of a DES.
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Background: Drug coated balloon (DCB) had efﬁcacy of in-stent restenosis ac-
cording to previous study. The areas of drug adhesion were not visible with angi-
ography, but optical frequency domain imaging (OFDI) could show them as high
intensity spots. The extent of drug adhesion was not always circumferential. The aim
of study was to investigate the association between lumen eccentricities and drug
adhesion after DCB inﬂation.
Methods: Patients with in-stent coronary artery restenosis were enrolled. OFDI was
performed at baseline, after pre dilatation and after DCB inﬂation. Pre dilatation
with usual balloon was performed followed by DCB treatment. Lumen eccentricity
was indicated by difference between maximum and minimum lumen diameter. The
ratio of drug adhesion area was represented by angle of the bright spot from light
source.
Results: 12 patients with restenosis lesion were analyzed in this study. Men were 10
(83.3 %), age was 68.7  5.529 years old. Left descending artery was 7 (58.3%), left
circumﬂex artery was 2 (16.7%) and right coronary artery was 3 (25.0%). The
restenosis stent was 1 bare metal stent (8.3%), 11 drug eluting stent (91.7%). The
difference of maximum and minimum lumen diameter just before DCB treatment was
inversely associated with drug adhesion (r¼-0.295, p¼0.004). Lower lumen diameter
difference group had more drug adhesion than higher group (p¼0.002).
Conclusions: Our study showed lumen eccentricity was associated with amount of
drug adhesion. It was ideal to be more concentric coronary lumen before DCB
inﬂation. Importance of pre dilatation was highlighted in our study.ug-Eluting Balloons and Local Drug Delivery B79
